Insulin-like factor 3 (INSL3): a new parameter to assess Leydig cell functionality and primary hypogonadismus in the EMAS population.

胰岛素样因子 3 (INSL3)：评估 EMAS 人群中 Leydig 细胞功能和原发性性腺功能减退症的新参数。

• 批准号: 242439839
• 负责人: Privatdozent Dr. Jens Vanselow, since 4/2014
• 金额: --
• 依托单位: Forschungsinstitut für Nutztierbiologie (FBN)
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2013
• 资助国家: 德国
• 起止时间: 2012-12-31 至 2018-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/242439839?language=en
• 关键词: Insulin; like; factor; INSL3; new

Insulin-like factor 3 (INSL3) is a constitutive product uniquely of the testicular Leydig cells. In adult men it is secreted into the blood in substantial amounts, thereby revealing the functional capacity of the Leydig cells in a way which is independent of testosterone and feedback via the HPG axis. It is thus an excellent and independent measure of Leydig cell capacity in health and disease, especially during aging. In collaboration with Professor Fred Wu from the University of Manchester and Coordinator of the EMAS (European Male Aging Study) project to research the physiology and clinical pathology of the aging European male, we plan to measure INSL3 in the two legs of the EMAS cohort (total ca. 6000 samples), allowing both cross-sectional as well as longitudinal correlation with the many biochemical and clinical parameters already obtained in this most extensive study of aging men from eight European centres. INSL3 measurement will not simply serve as an additional parameter, but will better help to define specific pathologies and clinically relevant groups of men.Hypoandrogenemia is at the core of pathologies associated with aging in men, however, testosterone as a clinical parameter is beset with many confounders, so that a hypogonadal causality in age-related symptoms is difficult to ascertain. Consequently, any recommendation for an androgen-based therapy is largely limited to a few extreme cases only. Because INSL3 is a robust and constitutive parameter which is largely independent of these androgen-related confounders, its measurement in the EMAS cohort will provide valuable insight into the role of testicular aging in the etiology of age-related pathologies such as metabolic syndrome or osteoporosis. The applicants draw on worldwide unique experience in the measurement of INSL3 in human (and animal) studies, and its clinical relevance.

胰岛素样因子3（INSL3）是睾丸leydig细胞的独特构成产物。在成年男性中，它被大量分泌到血液中，从而以独立于睾丸激素和通过HPG轴的方式揭示了Leydig细胞的功能能力。因此，它是健康和疾病中Leydig细胞能力的出色且独立的度量，尤其是在衰老期间。我们与曼彻斯特大学的弗雷德·吴教授以及EMAS（欧洲男性老龄化研究）的协调员（欧洲欧洲男性老龄化的生理学和临床病理学）的协调员，我们计划在EMAS群体的两条腿上测量INSL3（总计6000个样本），允许跨部门和许多持续的持续性参与者，以及许多跨越型的参与者，在许多Biotial and and the biochemational and the biochematial in and biochemation and in biochemation in对来自八个欧洲中心的老年男性的广泛研究。 INSL3测量不仅可以作为附加参数，还可以更好地帮助定义特定的病理和临床相关的男性组。Hypoandrogenemia是与男性衰老相关的病理学的核心，但是，睾丸激素作为临床参数与许多混杂因素困扰，因此在年龄段的人中有很多混淆，很难逐渐征服。因此，对基于雄激素的治疗​​的任何建议在很大程度上仅限于一些极端情况。由于INSL3是一个强大且本构的参数，在很大程度上与这些与雄激素相关的混杂因子很不独立，因此其在EMAS同类中的测量将提供宝贵的见解，以了解睾丸衰老在与年龄相关的病理学（如代谢综合征或骨质疏松症等年龄相关病因）中的病因中的作用。申请人在人类（和动物）研究中及其临床相关性中借鉴了全球独特的经验。